InfuSystem Posts Delayed Q3 Results: Revenue $37.6M, Adjusted EBITDA $9.4M, Guidance Reaffirmed
INFU sits 80% above its 52-week low of $7.29.
Summary
InfuSystem reported the Q3 2026 results it delayed on November 3: revenue of $37.6 million (up 3.0%, 10.2% pro forma), net income of $3.2 million and Adjusted EBITDA of $9.4 million, with full-year guidance reaffirmed.
Key Events · Earnings and Guidance · INFU
-
Delayed Q3 Results Released
Net revenue came in at $37.6 million, up 3.0% from $36.5 million, and net income was $3.2 million, or $0.15 per diluted share, versus $2.3 million, or $0.11 per diluted share a year earlier.
-
Pro-Forma Growth Accelerates
Excluding the restructured GE Healthcare contract, pro-forma revenue grew 10.2%, up from 1.7% in Q1 and 7.5% in Q2; Wound Care revenue rose $2.0 million, or 112%.
-
Margins Expand on Cost Cuts
Adjusted EBITDA rose 12.5% to $9.4 million and margin expanded to 24.9% from 22.8%, helped by lower costs from the GE Healthcare restructuring and tapering ERP project spend.
-
Guidance Reaffirmed
Full-year 2026 pro-forma revenue growth is still expected at 6% to 8%, with Adjusted EBITDA margins in the low-to-mid 20% range.
Analysis · INFU · Industrial Applications And Services
The Q3 2026 numbers InfuSystem held back on November 3 to review $4.2 million of ERP-related billing issues are now out, and they show no revenue problem. Net revenue rose 3.0% to $37.6 million, or 10.2% pro forma once the deliberately shrunk GE Healthcare contract is excluded, while Adjusted EBITDA climbed 12.5% to $9.4 million and margin expanded to 24.9%. Management reaffirmed full-year guidance of 6% to 8% pro-forma revenue growth and low-to-mid 20% Adjusted EBITDA margins. One item remains open: the working capital hit, with about $5.0 million of receivables tied up by the ERP billing disruption, of which roughly $1.3 million had converted to cash by October. Fourth-quarter cash conversion is the number to check against the November 10 call.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INFU was trading at $13.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $261.9M. The 52-week trading range was $7.29 to $14.64. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.